Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores.
Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment / Giacomucci, Giulia; Mazzeo, Salvatore; Bagnoli, Silvia; Ingannato, Assunta; Leccese, Deborah; Berti, Valentina; Padiglioni, Sonia; Galdo, Giulia; Ferrari, Camilla; Sorbi, Sandro; Bessi, Valentina; Nacmias, Benedetta. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 269:8(2022), pp. 4270-4280. [10.1007/s00415-022-11055-5]
Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment
Mazzeo, SalvatoreSecondo
;
2022-01-01
Abstract
Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores.| File | Dimensione | Formato | |
|---|---|---|---|
|
Giacomucci2022_Article_PlasmaNeurofilamentLightChainA.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
939.43 kB
Formato
Adobe PDF
|
939.43 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
